Webinar on Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention, Presented by Covalon

June 21, 2023

Registration now open: Save patient skin and stop cringeworthy dressing trauma

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced an expert-led webinar titled “Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention” will be held on Thursday, June 22, 2023 at 1pm ET.

​​​​​​​Whether it’s placing an IV-line, checking vitals, or administering life-saving treatment, patient care begins with the skin. Yet, medical adhesive related skin injury (MARSI) affects 1 in 5 vascular access patients, with rates of up to 55% in pediatric populations. MARSI occurs when medical adhesives – peeled away from raw, vulnerable skin – cause the surface layers of the skin to be torn. Damage to the skin doesn’t just cause pain, trauma, and ongoing discomfort; it can result in harmful bacteria finding their way into the skin tissues of surgical incisions, IV sites, or the patient’s bloodstream.

Healing shouldn’t hurt – and Covalon is able to provide compassionate care technology that can help hospitals move beyond traditional acrylic-based dressings that can create wounds, cause scarring and delay healing. Preventing and saving skin from reactions, tears, and burns is much easier than treating them. Healthcare practitioners are invited to join this webinar designed to highlight the challenges of medical adhesive-related skin injuries and best practices to protect patient skin and prevent infection.

Takeaways from the webinar include:

  • Insights into the challenges associated with MARSI
  • Best practices for maintaining skin integrity
  • New strategies and innovative technology to prevent MARSI

Webinar Details:

Title: Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention

Presentation by: Sandy M. Conn, BSN, RN, CPN, WCC, Wound and Skin Care Expert with over 30 years of experience in Pediatric Critical Care

Date: Thursday, June 22, 2023, 1pm ET
Registration Link:Addressing MARSI in Vascular Access
Hashtags: #MARSI, #infectionprevention, #compassionatecare

Choosing the right medical dressing for a patient can make the difference between pain vs comfort, infection vs healing, skin injury vs skin integrity. Covalon’s soft silicone dressings provide gentle, non-compromisingly effective care:

  • CovaClear ® IV – utilizes soft silicone adhesive technology to help protect patients from skin injuries, but does not incorporate antimicrobials, for use with patients who either do not require or cannot tolerate antimicrobials.
  • IV Clear ® - the world’s only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
  • SurgiClear ® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.

For healthcare providers who are not able to attend the webinar but are interested in learning more about Covalon’s solutions, visit www.covalon.com or follow Covalon on LinkedIn, Facebook, Instagram or Twitter.

About Covalon
Covalon Technologies Ltd. is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, we offer innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2022, which is available on the Company’s profile at www.sedar.com , any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

To learn more about Covalon, please contact:
Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll-Free: 1.877.711.6055
Website: https://covalon.com/
Twitter: @covalon

Source: Covalon Technologies Ltd.